Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDNA11 alone or with pembrolizumab in advanced solid tumors
NCT05086692Phase 2Active, not recruiting
- Sponsor
- Medicenna Therapeutics
- Start
- Aug 2021
- Primary completion
- Oct 2028
- Modality
- Cytokines & Interferons
- Countries
- 8
01
Overview
A Phase 2 trial of MDNA11 in solid tumor, sponsored by Medicenna Therapeutics. Started Aug 2021; status: active, not recruiting.
02
Drugs
MDNA11
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05086692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086692.